Published in J Nucl Med on February 01, 2005
Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med (2009) 1.27
18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging (2007) 1.25
Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med (2009) 1.22
Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med (2005) 1.20
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol (2009) 1.12
Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One (2013) 1.12
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 1.10
A review of imaging agent development. AAPS J (2009) 1.08
Brain tumors. Semin Nucl Med (2012) 1.05
Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases. J Nucl Med (2010) 1.04
Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging (2009) 1.02
Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia (2009) 0.99
Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res (2008) 0.96
The integration of quantitative multi-modality imaging data into mathematical models of tumors. Phys Med Biol (2010) 0.96
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med (2008) 0.92
Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med (2012) 0.92
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol (2008) 0.89
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res (2011) 0.87
Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging (2012) 0.87
Validity of simplified 3'-deoxy-3'-[18F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer. Mol Imaging Biol (2012) 0.86
Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol (2010) 0.85
Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med (2015) 0.85
Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials. Clin Transl Imaging (2014) 0.85
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. Int J Radiat Oncol Biol Phys (2015) 0.84
Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer. Mol Imaging Biol (2013) 0.82
FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol (2008) 0.82
Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice. EJNMMI Res (2013) 0.82
Cumulative input function method for linear compartmental models and spectral analysis in PET. J Cereb Blood Flow Metab (2010) 0.81
The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev (2008) 0.81
Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT. Phys Med Biol (2012) 0.78
The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture. Br J Radiol (2010) 0.78
Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging (2015) 0.77
Kinetic analysis of 18F-FLT PET in lung tumors. J Nucl Med (2012) 0.77
Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data. EJNMMI Res (2012) 0.76
Heterogeneity in stabilization phenomena in FLT PET images of canines. Phys Med Biol (2014) 0.76
Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity. Eur J Nucl Med Mol Imaging (2014) 0.76
(18) F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: a voxel-by-voxel PET kinetics study. Med Phys (2017) 0.76
Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer. EJNMMI Res (2015) 0.75
Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft. EJNMMI Res (2016) 0.75
Using dynamic contrast-enhanced magnetic resonance imaging data to constrain a positron emission tomography kinetic model: theory and simulations. Int J Biomed Imaging (2013) 0.75
Kinetic models for analysing myocardial [(11)C]palmitate data. Eur J Nucl Med Mol Imaging (2009) 0.75
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
PET-CT image registration in the chest using free-form deformations. IEEE Trans Med Imaging (2003) 3.79
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res (2006) 3.17
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res (2004) 3.13
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med (2002) 2.54
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther (2005) 2.35
A definition of molecular imaging. J Nucl Med (2007) 2.26
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol (2006) 2.12
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
Imaging oxygenation of human tumours. Eur Radiol (2006) 1.78
FDG PET, PET/CT, and breast cancer imaging. Radiographics (2007) 1.72
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res (2009) 1.70
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 1.68
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res (2008) 1.65
Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am (2005) 1.64
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol (2008) 1.60
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med (2005) 1.59
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med (2008) 1.57
Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med (2014) 1.52
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat (2007) 1.48
18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med (2004) 1.46
Locally advanced and inflammatory breast cancer. J Clin Oncol (2008) 1.44
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res (2007) 1.40
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med (2006) 1.40
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med (2008) 1.39
Radionuclide breast cancer imaging 2013: state of the art. Semin Nucl Med (2013) 1.39
SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med (2003) 1.37
Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol (2004) 1.34
Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med (2005) 1.33
Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med (2003) 1.32
Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun (2004) 1.30
Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol (2002) 1.30
PET imaging of cellular proliferation. Radiol Clin North Am (2005) 1.29
[11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol (2006) 1.29
Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med (2005) 1.28
Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med (2009) 1.27
Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med (2007) 1.27
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med (2003) 1.23
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.23
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med (2011) 1.23
Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med (2009) 1.21
Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med (2011) 1.21
Comparison of different quantitative approaches to 18F-fluoride PET scans. J Nucl Med (2004) 1.19
Tumor receptor imaging. J Nucl Med (2008) 1.19
FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. Semin Nucl Med (2007) 1.19
ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol (2013) 1.18
Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther (2006) 1.16
Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol (2004) 1.14
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res (2010) 1.13
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol (2009) 1.12
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res (2011) 1.12
Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med (2004) 1.11
Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol (2006) 1.10
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer (2005) 1.09
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol (2004) 1.08
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med (2004) 1.07
A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem (2010) 1.06
Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther (2004) 1.06
18F-Fluoroestradiol. Semin Nucl Med (2007) 1.06
Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases. J Nucl Med (2010) 1.04
Dynamic perifusion to maintain and assess isolated pancreatic islets. Diabetes Technol Ther (2002) 1.04
The FDG lumped constant in normal human brain. J Nucl Med (2002) 1.04
Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images. Math Med Biol (2011) 1.03
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med (2011) 1.02
PET/CT imaging in cancer: current applications and future directions. Cancer (2014) 1.02
Design considerations for using PET as a response measure in single site and multicenter clinical trials. Acad Radiol (2011) 1.02
Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem (2008) 1.02
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol (2011) 1.01
Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances. AJR Am J Roentgenol (2007) 1.01
Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med (2010) 1.00
Polyploidy road to therapy-induced cellular senescence and escape. Int J Cancer (2012) 0.99
Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med (2002) 0.99